New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

Cancer

Volumn 121, Issue 15, 2015, Pages 2517-2528

  Jabbour, Elias ^a   O'Brien, Susan ^a   Konopleva, Marina ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

acute lymphoblastic leukemia; management; outcome

Indexed keywords

CD20 ANTIGEN;

ADOLESCENT; ADULT; AGE; AGED; ALLOGRAFT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METABOLISM; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR GENE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLOGRAFTS; ANTIGENS, CD20; GENES, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 84937523007     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29383     Document Type: Review

References (92)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
3. Inaba H, Greaves M, Mullighan CG,. Acute lymphoblastic leukaemia. Lancet. 2013; 381: 1943-1955.
4. Pui CH, Campana D, Pei D, et al., Treating childhood leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.
5. Pui CH, Mullighan CG, Evans WE, Relling MV,. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012; 120: 1165-1174.
6. Kantarjian HM, Thomas D, O'Brien S, et al., Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 2788-2801.
7. Sive JI, Buck G, Fielding A, et al., Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG 2993 trial. Br J Haematol. 2012; 157: 463-471.
8. Hoelzer D, Walewski J, Dohner H, et al., Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014; 124: 3870-3879.
9. Thomas DA, Faderl S, O'Brien S, et al., Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
10. Thomas DA, O'Brien S, Faderl S, et al., Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010; 28: 3880-3889.
11. Fielding AK, Rowe JM, Buck G, et al., UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014; 123: 843-850.
12. Ravandi F, O'Brien S, Thomas D, et al., First report of phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010; 116: 2070-2077.
13. Jain P, Kantarjian H, Ravandi F, et al., The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014; 28: 973-975.
14. Mullighan CG, Su X, Zhang J, et al., Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360: 470-480.
15. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al., A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009; 10: 125-134.
16. Roberts KG, Li Y, Payne-Turner D, et al., Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371: 1005-1015.
17. Harvey RC, Mullighan CG, Chen IM, et al., Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010; 115: 5312-5321.
18. Mullighan CG, Collins-Underwood JR, Phillips LA, et al., Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009; 41: 1243-1246.
19. Russell LJ, Capasso M, Vater I, et al., Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009; 114: 2688-2698.
20. Roberts KG, Morin RD, Zhang J, et al., Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012; 22: 153-166.
21. Hertzberg L, Vendramini E, Ganmore I, et al., Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010; 115: 1006-1017.
22. Yoda A, Yoda Y, Chiaretti S, et al., Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010; 107: 252-257.
23. Roberts KG, Pei D, Campana D, et al., Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014; 32: 3012-3020.
24. Holmfeldt L, Wei L, Diaz-Flores E, et al., The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013; 45: 242-252.
25. Muhlbacher V, Zenger M, Schnittger S, et al., Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer. 2014; 53: 524-536.
26. Rizzieri DA, Johnson JL, Byrd JC, et al., Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B Study 10 002. Br J Haematol. 2014; 165: 102-111.
27. Dunleavy K, Pittaluga S, Shovlin M, et al., Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013; 369: 1915-1925.
28. Hoelzer D, Gokbuget N,. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev. 2012; 26: 25-32.
29. Arzerra (Ofatumumab) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
30. Jabbour E, Kantarjian H, Thomas D, et al., Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia [abstract]. J Clin Oncol. 2014; 32: 4024.
31. Dombret H, Gabert J, Boiron JM, et al., Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood. 2002; 100: 2357-2366.
32. Thomas DA, O'Brien SM, Faderl S, et al., Long-term outcome after hyper-CVA and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract]. J Clin Oncol. 2010; 28: 15s.
33. Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al., Long-term follow up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2013; 19: 150-155.
34. Bassan R, Rossi G, Pogliani EM, et al., Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010; 28: 3644-3652.
35. Pfeifer H, Goekbuget N, Volp C, et al., Long-term outcome of 335 patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) [abstract]. Blood. 2010; 116: 173.
36. Wassmann B, Pfeifer H, Goekbuget N, et al., Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006; 108: 1469-1477.
37. Kantarjian HM, Shah NP, Cortes JE, et al., Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119: 1123-1129.
38. Saglio G, Kim DW, Issaragrisil S, et al., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-2259.
39. Hu Y, Liu Y, Pelletier S, et al., Requirement of SRC kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004; 36: 453-461.
40. Chalandon Y, Thomas X, Hayette S, et al., Is less chemotherapy detrimental in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with high-dose imatinib? Results of the prospective randomized GRAAPH-2005 study [abstract]. Blood. 2012; 120 (suppl 1): 138.
41. Rousselot P, Coude MM, Huguet F, et al., Dasatinib and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 study [abstract]. Blood. 2012; 120 (suppl 1): 666.
42. Ottman OG, Pfeifer H, Cayuela JM, et al., Nilotinib (Tasigna) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1 positive acute lymphoblastic leukemia (ALL): a trial of the European Working Group for Adult ALL (EWALL-PH-02) [abstract]. Blood. 2014; 124: 798.
43. Chiaretti S, Vitale A, Elia L, et al., First results of the multicenter total therapy GIMEMA LAL 1509 protocol for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) patients [abstract]. Blood. 2014; 124: 797.
44. O'Hare T, Shakespeare WC, Zhu X, et al., AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009; 16: 401-412.
45. Cortes JE, Kantarjian H, Shah NP, et al., Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367: 2075-2088.
46. O'Brien S, Jabbour E, Thomas D, et al., Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients with Philadelphia chromosome positive acute lymphoblastic leukemia [abstract]. J Clin Oncol. 2014; 32: 7064.
47. Ravandi F, Jorgensen JL, Thomas DA, et al., Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013; 122: 1214-1221.
48. DeAngelo DJ,. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2009; 23: 1121-1135.
49. Arranon (Nelarabine) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
50. Coustan-Smith E, Mullighan CG, Onciu M, et al., Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10: 147-156.
51. Neumann M, Heesch S, Schlee C, et al., Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood. 2013; 121: 4749-4752.
52. Zhang J, Ding L, Holmfeldt L, et al., The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481: 157-163.
53. Stock W, La M, Sanford B, et al., What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112: 1646-1654.
54. Stock W, Luger SM, Advani AS, et al., Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. intergroup trial C10403 [abstract]. Blood. 2014; 124: 796.
55. Huguet F, Leguay T, Raffoux E, et al., Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009; 27: 911-918.
56. Patel B, Kirkwood A, Dey A, et al., Peg-asparaginase during induction in adult ALL (UKALL14) [abstract]. Blood. 2013; 122: 3900.
57. Rytting ME, Thomas DA, O'Brien SM, et al., Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia. Cancer. 2014; 120: 3660-3668.
58. O'Brien S, Thomas D, Ravandi F, et al., Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008; 113: 2097-2101.
59. Gokbuget N, Beck J, Bruggemann M, et al., Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL) [abstract]. Blood. 2012; 120: 1493.
60. Jabbour E, O'Brien S, Thomas D, et al., Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for elderly patients with acute lymphoblastic leukemia [abstract]. Blood. 2014; 124: 428.
61. Goldstone AH, Richards SM, Lazarus HM, et al., In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from a matched sibling allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII/ECOG 2993). Blood. 2008; 111: 1827-1833.
62. Campana D,. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010: 7-12.
63. Bassan R, Spinelli O, Oldani E, et al., Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009; 113: 4153-1162.
64. Bruggemann M, Raff T, Flohr T, et al., Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006; 107: 1116-1123.
65. Raff T, Gokbuget N, Luschen S, et al., Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007; 109: 910-915.
66. Borowitz MJ, Devidas M, Hunger SP, et al., Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111: 5477-5485.
67. Van der Velden VH, Corral L, Valsecchi MG, et al., Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009; 23: 1073-1079.
68. Conter V, Bartram CR, Valsecchi MG, et al., Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115: 3206-3214.
69. Gokbuget N, Kneba M, Raff T, et al., Adults with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012; 120: 1868-1876.
70. Ribera JM, Oriol A, Morgades M, et al., Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014; 32: 1595-1604.
71. Nagorsen D, Kufer P, Baeuerle PA, Bargou R,. Blinatumomab: a historical perspective. Pharmacol Ther. 2012; 136: 334-342.
72. Topp MS, Kufer P, Gokbuget N, et al., Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29: 2493-2498.
73. Topp MS, Gokbuget N, Zugmaier G, et al., Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012; 120: 5185-5187.
74. Goekbuget N, Dombret H, Bonifacio M, et al., BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2014; 124: 379.
75. Thomas DA, Kantarjian H, Smith TL, et al., Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999; 86: 1216-1230.
76. Tavernier E, Boiron JM, Huguet F, et al., Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007; 21: 1907-1914.
77. Gokbuget N, Stanze D, Beck J, et al., Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012; 120: 2032-2041.
78. Topp M, Gokbuget N, Zugmaier G, et al., Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32: 4134-4140.
79. Topp MS, Goekbuget N, Stein AS, et al., Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16: 57-66.
80. Thomas X,. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Investig Drugs. 2012; 21: 871-878.
81. Advani A, Coiffier B, Czuczman MS, et al., Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010; 28: 2085-2093.
82. Kantarjian H, Thomas D, Jorgensen J, et al., Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012; 13: 403-411.
83. Kebriaei P, Wilhelm K, Ravandi F, et al., Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013; 13: 296-301.
84. Kantarjian H, Thomas D, Jorgensen J, et al., Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013; 119: 2728-2736.
85. Jabbour E, O'Brien S, Huang X, et al., Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015; 90: 193-196.
86. Advani AS, Stein AS, Kantarjian HM, et al., A phase II study of weekly inotuzumab ozogamicin in adult patients with Cd22-positive acute lymphoblastic leukemia in second or later salvage [abstract]. Blood. 2014; 124: 2255.
87. Porter DL, Levine BL, Kalos M, et al., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365: 725-733.
88. Grupp SA, Kalos M, Barrett D, et al., Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368: 1509-1518.
89. Maude SL, Frey N, Shaw PA, et al., Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507-1517.
90. Lee DW, Shah NN, Stetler-Stevenson M, et al., T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385: 517-528.
91. Davila M, Riviere I, Wang X, et al., Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6: 224ra25.
92. Turtle CJ, Sommermeyer D, Berger C, et al., Therapy of B cell malignancies with CD19-specific chimeric antigen receptor-modified T cells of defined subset composition [abstract]. Blood. 2014; 124: 384.